Clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy
Abstract Background Neoadjuvant chemotherapy (NAC) is widely used in advanced breast cancer patients. However, there is little known about conversion frequency of estrogen receptor (ER) and/or progesterone receptor (PR) status for hormone receptor positive-breast cancer patients after NAC and their...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2018-03-01
|
| Series: | World Journal of Surgical Oncology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12957-018-1332-7 |
| _version_ | 1818136993725415424 |
|---|---|
| author | Libo Yang Xiaorong Zhong Tianjie Pu Yan Qiu Feng Ye Hong Bu |
| author_facet | Libo Yang Xiaorong Zhong Tianjie Pu Yan Qiu Feng Ye Hong Bu |
| author_sort | Libo Yang |
| collection | DOAJ |
| description | Abstract Background Neoadjuvant chemotherapy (NAC) is widely used in advanced breast cancer patients. However, there is little known about conversion frequency of estrogen receptor (ER) and/or progesterone receptor (PR) status for hormone receptor positive-breast cancer patients after NAC and their correlation with prognosis. Methods In this study, 231 breast cancer patients with residual disease after NAC were enrolled and divided into receptor stable group (having no conversion in both ER and PR status pre- and post-NAC) and any receptor conversion group (having any conversion in either ER or PR status). Univariate and multivariate survival analyses were used to compare survival differences between the two groups. Results Fifty-five patients (23.8%) had ER and/or PR conversion after NAC. Younger patients (≤ 50 years) were more likely to have receptor conversion (P = 0.014). For 213 patients (92.2%) who received adjuvant endocrinotherapy after surgery, the 5-year disease free survival (DFS) estimates for patients in the any receptor conversion group (55.2%) was worse than patients in the receptor stable group (73.7%, Log-rank test, P = 0.015). While the 5-year overall survival estimates for patients with or without receptor conversion were not statistically different (86.0 vs. 82.4%, Log-rank test, P = 0.587). In multivariate Cox proportional hazard analyses, patients with any receptor conversion had worse DFS (hazard ratio, 1.995; 95% confidence interval, 1.130–3.521, P = 0.031). Conclusions It is necessary to recommend patients to test biomarkers in residual disease and pay more attention to patients who have any receptor conversion. These patients may need more individual therapy after surgery. |
| first_indexed | 2024-12-11T09:49:14Z |
| format | Article |
| id | doaj.art-863c911d49204832af419509ca495cca |
| institution | Directory Open Access Journal |
| issn | 1477-7819 |
| language | English |
| last_indexed | 2024-12-11T09:49:14Z |
| publishDate | 2018-03-01 |
| publisher | BMC |
| record_format | Article |
| series | World Journal of Surgical Oncology |
| spelling | doaj.art-863c911d49204832af419509ca495cca2022-12-22T01:12:28ZengBMCWorld Journal of Surgical Oncology1477-78192018-03-011611910.1186/s12957-018-1332-7Clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapyLibo Yang0Xiaorong Zhong1Tianjie Pu2Yan Qiu3Feng Ye4Hong Bu5Department of Pathology, West China Hospital, Sichuan UniversityDepartments of Head and Neck and Mammary Gland Oncology, and Medical Oncology, Cancer Center, West China Hospital, Sichuan UniversityDepartment of Pathology, West China Hospital, Sichuan UniversityDepartment of Pathology, West China Hospital, Sichuan UniversityLaboratory of Pathology, West China Hospital, Sichuan UniversityDepartment of Pathology, West China Hospital, Sichuan UniversityAbstract Background Neoadjuvant chemotherapy (NAC) is widely used in advanced breast cancer patients. However, there is little known about conversion frequency of estrogen receptor (ER) and/or progesterone receptor (PR) status for hormone receptor positive-breast cancer patients after NAC and their correlation with prognosis. Methods In this study, 231 breast cancer patients with residual disease after NAC were enrolled and divided into receptor stable group (having no conversion in both ER and PR status pre- and post-NAC) and any receptor conversion group (having any conversion in either ER or PR status). Univariate and multivariate survival analyses were used to compare survival differences between the two groups. Results Fifty-five patients (23.8%) had ER and/or PR conversion after NAC. Younger patients (≤ 50 years) were more likely to have receptor conversion (P = 0.014). For 213 patients (92.2%) who received adjuvant endocrinotherapy after surgery, the 5-year disease free survival (DFS) estimates for patients in the any receptor conversion group (55.2%) was worse than patients in the receptor stable group (73.7%, Log-rank test, P = 0.015). While the 5-year overall survival estimates for patients with or without receptor conversion were not statistically different (86.0 vs. 82.4%, Log-rank test, P = 0.587). In multivariate Cox proportional hazard analyses, patients with any receptor conversion had worse DFS (hazard ratio, 1.995; 95% confidence interval, 1.130–3.521, P = 0.031). Conclusions It is necessary to recommend patients to test biomarkers in residual disease and pay more attention to patients who have any receptor conversion. These patients may need more individual therapy after surgery.http://link.springer.com/article/10.1186/s12957-018-1332-7Breast cancerNeoadjuvant chemotherapyHormone receptorReceptor conversion |
| spellingShingle | Libo Yang Xiaorong Zhong Tianjie Pu Yan Qiu Feng Ye Hong Bu Clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy World Journal of Surgical Oncology Breast cancer Neoadjuvant chemotherapy Hormone receptor Receptor conversion |
| title | Clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy |
| title_full | Clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy |
| title_fullStr | Clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy |
| title_full_unstemmed | Clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy |
| title_short | Clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy |
| title_sort | clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy |
| topic | Breast cancer Neoadjuvant chemotherapy Hormone receptor Receptor conversion |
| url | http://link.springer.com/article/10.1186/s12957-018-1332-7 |
| work_keys_str_mv | AT liboyang clinicalsignificanceandprognosticvalueofreceptorconversioninhormonereceptorpositivebreastcancersafterneoadjuvantchemotherapy AT xiaorongzhong clinicalsignificanceandprognosticvalueofreceptorconversioninhormonereceptorpositivebreastcancersafterneoadjuvantchemotherapy AT tianjiepu clinicalsignificanceandprognosticvalueofreceptorconversioninhormonereceptorpositivebreastcancersafterneoadjuvantchemotherapy AT yanqiu clinicalsignificanceandprognosticvalueofreceptorconversioninhormonereceptorpositivebreastcancersafterneoadjuvantchemotherapy AT fengye clinicalsignificanceandprognosticvalueofreceptorconversioninhormonereceptorpositivebreastcancersafterneoadjuvantchemotherapy AT hongbu clinicalsignificanceandprognosticvalueofreceptorconversioninhormonereceptorpositivebreastcancersafterneoadjuvantchemotherapy |